AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01747538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2 gevokizumab
Description: Solution for subcutaneous injection
Study NCT00704340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DuraSeal Dural Sealant System
Description: The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel. DuraSeal should only be used with autologous duraplasty material.
Study NCT00704340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator.
Study NCT03345979 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil
Description: Intramuscular injection; study drug provided using a pre-filled syringe
Study NCT03345979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone Palmitate
Description: Intramuscular injection
Study NCT01586416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Two or three one-hour sessions of an individual behavioral intervention led by a doctoral-level licensed psychologist during the first 12 weeks of chemotherapy. Intervention addresses modifiable behaviors for managing chemotherapy challenges.
Study NCT02671565 — intervention group
Intervention type: DRUG
Intervention: Hyaluronic Acid injections
Study NCT04680949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Standard-of-care and anakinra. Anakinra is injected subcutaneously as 100 mg once daily for 10 days
Study NCT04680949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard-of-care and placebo. Placebo is injected subcutaneously once daily for 10 days
Study NCT02452203 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Floating
Description: Floating in either a pool saturated with Epsom salt or in a zero-gravity chair
Study NCT02452203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Floating
Description: Floating in either a pool saturated with Epsom salt or in a zero-gravity chair
Study NCT00738257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronate
Study NCT02871323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT02871323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01662219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block for experimental group
Description: 15 ml of 0.25% Bupivacaine will be given for superficial cervical plexus block
Study NCT03196245 — intervention group
Intervention type: OTHER
Intervention: There is no intervention.
Description: There is no intervention. This is a purely observational study. We enrolled pregnant women as they received a vaccine as part of their regular medical care; we did not administer the vaccine. We also enrolled pregnant women acutely infected with influenza.
Study NCT01375179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRP203
Study NCT02208349 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: King Video Laryngoscope
Description: We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
Study NCT02208349 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional direct laryngoscopy (DL)
Study NCT01158690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resource card
Description: the intervention group receives an envelop with resource card
Study NCT01158690 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no resource card
Description: the control group receives an envelop without resource card
Study NCT04912752 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Migraine CNV
Description: Copy number variation effect on migraine disease
Study NCT04912752 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Migraine CNV
Description: Copy number variation effect on migraine disease
Study NCT03795090 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Regular Patient privacy curtain
Description: Laundered curtains, used in the hospital, coming from the hospital inventory.
Study NCT03795090 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Regular Patient privacy curtain
Description: Laundered curtains, used in the hospital, coming from the hospital inventory.
Study NCT03795090 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Antimicrobial Coated curtains
Description: Antimicrobial coating consist of active polymers that are approved by USFDA and USEPA.
Study NCT03038893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point Of Care Ultrasound (PODUS)
Description: Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
Study NCT03038893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Echo Doppler Ultrasound (EDUS)
Description: Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
Study NCT01055483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat/LBH589B
Study NCT02782767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wound catheter infusion
Description: Wound catheter has multiple holes spread around 360 degrees throughout its active length. It is placed in the musculofascial plane during closure of the wound. Local anaesthetic infusion will be delivered through the catheter.
Study NCT02782767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural infusion
Description: Epidural catheter will be placed in the level T7-T9 , and local anaesthetic infusion will be given
Study NCT04001972 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice (AWARD model)
Description: Ask: smoking habit, quit intention and attempt, smoking reduction intention, previous quitting experience including NRT and SC use.~Warn: smokers will be orally warned about the harms of smoking and receive a A5-sized leaflet, which includes some shocking pictures of smoking-related diseases, and SC services information.~Advise: smokers will be advised to quit as soon as possible and use NRT or SC services.~Refer: smokers will be encouraged to seek SC services for free NRT or other SC services. Those who agreed will be actively referred to their preferred SC services. The collected contact information with consent will be sent to the SC services providers for a quick appointment and follow-up.~Do-it-again: Relapsed smokers (identified during follow-ups and IM conversation) will receive the Advise and Refer intervention.
Study NCT03274492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT03274492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT03274492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT03274492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vincristine
Description: Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT04001972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief advice (AWARD model)
Description: Ask: smoking habit, quit intention and attempt, smoking reduction intention, previous quitting experience including NRT and SC use.~Warn: smokers will be orally warned about the harms of smoking and receive a A5-sized leaflet, which includes some shocking pictures of smoking-related diseases, and SC services information.~Advise: smokers will be advised to quit as soon as possible and use NRT or SC services.~Refer: smokers will be encouraged to seek SC services for free NRT or other SC services. Those who agreed will be actively referred to their preferred SC services. The collected contact information with consent will be sent to the SC services providers for a quick appointment and follow-up.~Do-it-again: Relapsed smokers (identified during follow-ups and IM conversation) will receive the Advise and Refer intervention.
Study NCT04001972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRT-S
Description: One-week free NRT (gum or patch) will be provided with dosage based on time to first cigarette smoking after waking up in the morning and previous NRT use (standard practice and according to specific NRT product instructions). Subjects who have first cigarette \<30 minutes in the morning or have previously used NRT, will receive 4mg nicotine gum or 21mg nicotine patch. Those who have first cigarette >30 minutes after waking up and have not previously used NRT will receive 2mg nicotine gum or 14mg nicotine patch. NRT use and potential side effects will be briefly explained orally based on standardized script according to the product instructions. An NRT use card containing reminders of NRT use and potential side effects will be given.
Study NCT04001972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IM Apps and Chatbot
Description: Twelve-week personalized behavioral support will be delivered using interactive communication technologies using (1) regular tailored messages on abstinence, and (2) synchronous IM Apps conversation with trained SC advisors, and (3) a Chatbot: A Chatbot will be built using open source NLP and machine intelligence platforms. The unstructured text data from our previous study (ClinicalTrials.gov ID: NCT03182790) will be used to train the proposed Chatbot. We will draft responses for each identified question. The final version will be incorporated with Application Programming Interface (API) integration into user-friendly apps (iOS/Android/web app) with a backend server support and continuous data collection for potential bigdata analysis.
Study NCT04001972 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular SMS message
Description: Regular SMS messages focus on general health and remind the importance of participating in the follow-up surveys and biochemical validation for quitting
Study NCT03066167 — intervention group
Intervention type: OTHER
Intervention: Validation of different dysphagia scores
Study NCT04023682 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Provodine Hand Sanitizer
Description: Intervention with Provodine
Study NCT03495791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YouTube Video
Description: Educational Video
Study NCT04524624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-based CDSS
Description: 1. Automatically identifying acute ischemic stroke lesions on DWI.~2. Classification of stroke subtypes and mechanisms.~3. Evidence-based alerts and guidelines for early stroke management.~4. Guideline-recommended secondary stroke prevention strategies.
Study NCT03274492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Placebo
Description: Placebo matching to vincristine will be administered as per the schedule specified in the respective arm.
Study NCT04254120 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: Psychological treatment focusing on changing cognitions and behaviors using information processing theory and learning theory approaches.
Study NCT04254120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated motivational interviewing and cognitive-behavioral therapy
Description: Motivational interviewing is a psychological treatment approach focusing on increasing motivation by eliciting patient talk favoring behavior change and resolving patient ambivalence about change.
Study NCT01291277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Variceal Ligation
Description: Ligation of esophageal varices
Study NCT02127177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure Ventilator
Description: CPAP group received fixed-level CPAP titration using an automated pressure setting device for one night. The optimal CPAP pressure for each patient in the CPAP group was set at the minimum pressure required to abolish snoring, obstructive respiratory events, and airflow limitation for 95% of the night, according to a previous validation by our study.
Study NCT01725243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin IV, over 1 minute following delivery. Doses: 10, 20, 40, 60, 80, 100, 120 or 140mcg
Study NCT03274492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.
Study NCT03274492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.
Study NCT03274492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polatuzumab vedotin Placebo
Description: Placebo matching to polatuzumab vedotin will be administered as per the schedule specified in the respective arm.
Study NCT03814057 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 24 hour urine creatinine excretion
Description: two age corrected calculations of creatinine height index were obtained
Study NCT00326976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX06
Description: 400 mg as intravenous injection in two divided boluses
Study NCT00326976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FX06
Description: 400 mg as intravenous injection in two divided boluses
Study NCT00326976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Study NCT00326976 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous coronary intervention
Study NCT04467866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Ride-on Car with a Standing Posture
Description: The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
Study NCT04467866 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular Therapy Program
Description: The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks. Each participant will have the opportunity to walk on the hallway/public space and interact with the therapist and caregivers depending on his/her motor abilities.
Study NCT01375179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching KRP203
Study NCT01709539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostiskt Centrum
Description: Patients who are suspected of having cancer after investigation at the primary care center will be referred to Diagnostiskt Centrum. Each patient who is referred to Diagnostiskt Centrum will undergo the following: (1) clinical chemistry/microbiology tests; (2) medical history; (3) objective clinical examination; and (4) taking of blood samples for analysis of biomarkers. If necessary, patients will also undergo the following: (5) additional laboratory tests; (6) biopsy; (7) X-ray of painful joints; (8) CT scan of the neck, thorax, abdomen, and/or pelvis; (9) mammography and gynecological examination; (10); gastroscopy and/or colonoscopy; and (11) further investigation (e.g., PET-CT scan).
Study NCT03322540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously every 3 weeks.
Study NCT03322540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously every 3 weeks.
Study NCT03322540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat administered orally twice daily.
Study NCT00716742 — intervention group
Intervention type: DRUG
Intervention: bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
Description: 1 drop in eye(s) every evening
Study NCT03070821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rtfMRI neurofeedback training
Description: Information about the state of brain activation was given to subjects. That information was visualised as a thermometer bar. Subjects tried to modulate that activation while performing a mental imagery task.
Study NCT03070821 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: rtfMRI neurofeedback training
Description: Information about the state of brain activation was given to subjects. That information was visualised as a thermometer bar. Subjects tried to modulate that activation while performing a mental imagery task.
Study NCT03070821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3T MRI
Description: A 3T Siemens MRI scanner was used to implement rtfMRI neurofeedback training.
Study NCT03070821 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 3T MRI
Description: A 3T Siemens MRI scanner was used to implement rtfMRI neurofeedback training.
Study NCT04014127 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary flow reserve assessment
Description: Coronary flow reserve will be assessed using Doppler transthoracic echocardiograpy and myocardial contrast echocardiography.
Study NCT03322540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally twice daily.
Study NCT03066505 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active MeRT Treatment
Description: A personalized biometrics-guided protocol known as magnetic EEG/EKG resonance therapy (MeRT) treatment that is tailored specifically to each patient's higher harmonic frequency of heart rate, which is nearest to the characteristic frequency of alpha EEG frequency.
Study NCT03066505 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham MeRT Treatment
Description: A personalized biometrics-guided protocol similar to MeRT treatment that mimics magnetic EEG/EKG resonance therapy (MeRT) but does not emit active stimulation.
Study NCT03281239 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laser doppler, blood tests, and holter ECG
Description: Diagnostic tests :~* laser doppler~* blood tests~* Holter ECG. No drug and no placebo were used in this arm.
Study NCT03024944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-THK-5351
Description: Intravenous (IV) catheter (tube) placed in participant arm. A small amount of 18F-THK-5351 will be injected into the IV enough time has passed for this contrast to collect in the tissue in the brain (approximately one half-hour), and participant will lie on a bed which slides into a PET Scanner to complete Tau imaging.
Study NCT00757354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metal on Metal cementless hip
Description: Metal on Metal hip arthroplasty
Study NCT02616172 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Infusion
Description: The subjects autologous bone marrow cells harvested at Florida Hospital will be infused intravenously by gravity
Study NCT04613284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin (Endostar)
Description: Continuous intravenous infusion of endostar (Simcere Pharma- ceutical, Nanjing, China) was made over 120 h before the begin- ning of radiotherapy, and then repeated every two weeks. The dose was 7.5 mg/m2/24 h 120 h, 14 days/cycle. ECG monitoring was performed during the first delivery of endostar.
Study NCT04014127 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sphygmocor
Description: Pulse wave analysis and pulse wave velocity will be assessed using the Sphygmocor device
Study NCT04613284 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic irradiation of 50 Gy with 3DCRT or IMRT
Description: Concurrent thoracic chemoradiotherapy with reduced irradiation dose of 50 Gy will be given to patients with unresectable stage III NSCLC who can not tolerate irradiation dose to 60 Gy.